ABUS (Arbutus Biopharma Corporation Common Stock) Stock Analysis - Analyst Ratings

Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 21, 2026, ABUS trades at $4.36 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate ABUS?

The average price target is $0.00.

ABUS Key Metrics

Key financial metrics for ABUS
MetricValue
Price$4.36
Market Cap$823.73M
P/E Ratio5.20
EPS$0.84
Dividend Yield0.00%
52-Week High$5.10
52-Week Low$2.71
Volume2.19M
Avg Volume0
Revenue (TTM)$191.44M
Net Income$160.72M
Gross Margin0.00%

ABUS Analyst Consensus

ABUS analyst coverage data. Average price target: $0.00.

Latest ABUS News

Recent ABUS Insider Trades

  • HASTINGS DAVID C sold 22.18K (~$72.83K) on Feb 4, 2025.
  • Sims Karen sold 19.35K (~$63.52K) on Feb 4, 2025.
  • McElhaugh Michael J. sold 23.79K (~$78.10K) on Feb 4, 2025.

Common questions about ABUS

What do analysts rate ABUS?
The average price target is $0.00.
Does Rallies show ABUS price targets?
Yes. Rallies tracks ABUS analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is ABUS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ABUS. It does not provide personalized investment advice.
ABUS

ABUS